Evidence map›Paper›PMID 33430964›Full record

ArticleJournal of cheminformatics2020

Industry-scale application and evaluation of deep learning for drug target prediction.

Noé Sturm, Andreas Mayr, Thanh Le Van, Vladimir Chupakhin, Hugo Ceulemans, Joerg Wegner, Jose-Felipe Golib-Dzib, Nina Jeliazkova, Yves Vandriessche, Stanislav Böhm and 9 more

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. In silico Methods for Identification of Potential Therapeutic Targets.Interdisciplinary sciences, computational life sciences · 2022
    Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Noé SturmClinical Pharmacology and Safety Science, R&D BioPharmaceuticals, AstraZeneca, Pepparedsleden 1, 43183, Mölndal, Sweden. noesturm@gmail.com.
Andreas MayrLIT AI Lab & Institute for Machine Learning, Johannes Kepler University Linz, Altenberger Str. 69, 4040, Linz, Austria.
Thanh Le VanHigh-Dimensional Biology & Discovery Data Sciences, Discovery Sciences, Janssen Pharmaceutica, Turnhoutseweg 30, 2349, Beerse, Belgium.
Vladimir ChupakhinHigh-Dimensional Biology & Discovery Data Sciences, Discovery Sciences, Janssen R&D, 1400 McKean Rd, Spring House, Pennsylvania, 19002, USA.
Hugo CeulemansHigh-Dimensional Biology & Discovery Data Sciences, Discovery Sciences, Janssen Pharmaceutica, Turnhoutseweg 30, 2349, Beerse, Belgium.
Joerg WegnerHigh-Dimensional Biology & Discovery Data Sciences, Discovery Sciences, Janssen Pharmaceutica, Turnhoutseweg 30, 2349, Beerse, Belgium.
Jose-Felipe Golib-DzibHigh-Dimensional Biology & Discovery Data Sciences, Discovery Sciences, Janssen Cilag SA, Calle Río Jarama, 75A, 45007, Toledo, Spain.
Nina JeliazkovaIdeaconsult Ltd., 4. Angel Kanchev Str., 1000, Sofia, Bulgaria.
Yves VandriesscheIntel Corporation, Data Center Group, Veldkant 31, 2550, Kontich, Belgium.
Stanislav BöhmIT4Innovations, VSB - Technical University of Ostrava, 17. Listopadu 2172/15, 70800, Ostrava-Poruba, Czech Republic.
Vojtech CimaIT4Innovations, VSB - Technical University of Ostrava, 17. Listopadu 2172/15, 70800, Ostrava-Poruba, Czech Republic.
Jan MartinovicIT4Innovations, VSB - Technical University of Ostrava, 17. Listopadu 2172/15, 70800, Ostrava-Poruba, Czech Republic.
Nigel GreeneClinical Pharmacology and Safety Science, R&D BioPharmaceuticals, AstraZeneca, Pepparedsleden 1, 43183, Mölndal, Sweden.
Tom Vander AaExascience Lab, Imec, Kapeldreef 75, 3001, Louvain, Belgium.
Thomas J AshbyExascience Lab, Imec, Kapeldreef 75, 3001, Louvain, Belgium.
Sepp HochreiterLIT AI Lab & Institute for Machine Learning, Johannes Kepler University Linz, Altenberger Str. 69, 4040, Linz, Austria.
Ola EngkvistHit Discovery, Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Pepparedsleden 1, 43183, Mölndal, Sweden.
Günter KlambauerLIT AI Lab & Institute for Machine Learning, Johannes Kepler University Linz, Altenberger Str. 69, 4040, Linz, Austria. klambauer@ml.jku.at.
Hongming ChenHit Discovery, Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Pepparedsleden 1, 43183, Mölndal, Sweden. Hongming.Chen71@hotmail.com.

Funding

Austrian Science Fund FWF P 28660Horizon 2020 Framework Programme 671555Large Infrastructures for Research, Experimental Development and Innovation IT4Innovation National Supercomputing Center - LM2015070
6 · The paper itself

Abstract

Artificial intelligence (AI) is undergoing a revolution thanks to the breakthroughs of machine learning algorithms in computer vision, speech recognition, natural language processing and generative modelling. Recent works on publicly available pharmaceutical data showed that AI methods are highly promising for Drug Target prediction. However, the quality of public data might be different than that of industry data due to different labs reporting measurements, different measurement techniques, fewer samples and less diverse and specialized assays. As part of a European funded project (ExCAPE), that brought together expertise from pharmaceutical industry, machine learning, and high-performance computing, we investigated how well machine learning models obtained from public data can be transferred to internal pharmaceutical industry data. Our results show that machine learning models trained on public data can indeed maintain their predictive power to a large degree when applied to industry data. Moreover, we observed that deep learning derived machine learning models outperformed comparable models, which were trained by other machine learning algorithms, when applied to internal pharmaceutical company datasets. To our knowledge, this is the first large-scale study evaluating the potential of machine learning and especially deep learning directly at the level of industry-scale settings and moreover investigating the transferability of publicly learned target prediction models towards industrial bioactivity prediction pipelines.

Indexed as

Big dataChEMBLCheminformaticsDeep learningMachine learningProspective evaluationPubChemQSARRetrospective evaluationStructure-based virtual screening

Identifiers

PMID33430964
PMCPMC7169028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.